key: cord-0832308-l1q4uvxl
authors: Borlongan, Mia C.; Borlongan, Maximillian C.; Sanberg, Paul R.
title: The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy
date: 2020-08-25
journal: Cell Transplant
DOI: 10.1177/0963689720940719
sha: 5c2cede17c25750ef19ccefb6c2f91bf4efb1501
doc_id: 832308
cord_uid: l1q4uvxl

Coronavirus disease 2019 or COVID-19 is highly infectious, which can lead to acute and chronic debilitating symptoms, as well as mortality. The advent of safe and effective vaccines or antiviral drugs remains distant in the future. Practical public health measures, such as social distancing, hand washing, and wearing a face mask, are the current recommended guidelines by the Centers for Disease Control and Prevention for limiting the spread of the virus. Weakened immune system and aberrant inflammation represent a major pathological symptom of COVID-19 patients. Based on the unique immunomodulatory properties of both convalescent plasma and stem cells, we discuss here their potential use for treating COVID-19.

may be likely accounted for by human behavior, especially those who do not take seriously the Centers for Disease Control and Prevention (CDC)-recommended public health practices of social distancing and proper hygiene, i.e., washing of hands with soap and water. Moreover, the virusassociated microdroplets can stay airborne for up to 3 h 6 , necessitating the need for wearing a face mask to protect ourselves and others. The combination of 6-feet social distancing, 20-s hand washing, and wearing N-95 or other CDC-recommended face masks has been reported to curve the spread of virus 7, 8 , but quantifying the risk of reducing these strategies remains debatable. Notwithstanding, the CDC continues to stress practicing social distancing, hand washing, and wearing a face mask in order to inhibit future deaths from the virus. Otherwise, we are living in our "disillusioned comfort," similar to the misguided security blanket we afford to negative consequences of smoking, gambling, and riding a motorcycle.

A historical review of virus-related pandemics reminds us of the 1918 Spanish flu, which infected 500 million and estimated to have killed about 17 million to 50 million people 9 . The Spanish flu resembles COVID-19: both are respiratory viruses with the precursor viruses mutating in animals thereafter infecting humans, and with fast-progressive cases from infection to symptom onset with viral consolidation in the lung and eventually mortality primarily from pneumonia 9-12 . Eerily enough, the key promoters of such high mortality rate of Spanish flu were overcrowding and poor hygiene-the same two factors that define our disillusioned comfort for COVID-19. Human behavior to the Spanish flu outbreak stands as the major determinant for the pattern of the pandemic's high mortality rate 13 . Again, the same human response, or lack thereof, that faces COVID-19.

A Spanish flu vaccine was not available during the 1918 pandemic, with the virus remaining largely unknown for almost a century when the molecular underpinnings of the virus were finally characterized in 2005 14 . Similar to COVID-19, the 1918 Spanish flu was first detected in the month of January, but after the second wave in August of that year, the number of cases dropped significantly and almost disappeared by the year's end. Without a vaccine, the rapid decline in infection and mortality after the second of the two lethal waves of Spanish flu was attributed to better treatment of pneumonia and the virus mutating to a less dangerous strain.

Three key lessons from the Spanish flu pandemic are worthy of consideration. First, those who survived the first wave developed immunity against the virus; thus, these individuals were immune to the second wave of the Spanish flu, providing us a glimpse on the future of passive immunitybased treatment against the virus. Indeed, clinical trials have recently been initiated using plasma collected from recovered COVID-19 patients based on the concept that these individuals have likely harbored strong immune responses such as antibodies that target the proteins found on COVID-19 15 . Second, that the end of Spanish flu cases by 1920 might have signaled the eradication of the pandemic may not be completely true. Evidence of slow-progressive cases of Spanish flu has been linked to secondary bacterial pneumonia, possibly affecting the brain, which results in neurological disorders, in particular encephalitis lethargica, that recorded its outbreak in the 1920s, in children 16 , which was suggested to manifest in adulthood as Parkinson's disease 17 but such a pathological link being merely coincidental has been debated 18 . Similarly, the potential long-term consequences of COVID-19 to brain disorders, and other comorbid diseases, warrant critical research avenues as we tackle this pandemic and its associated not-so-apparent mini outbreaks. Third, that overcrowding in military camps and lack of sanitation due to poverty during World War I contributed to Spanish flu pandemic draws our attention to the key pressing issue of human behavior.

Regenerative medicine may play a key role in treating COVID-19. The ongoing clinical trials of infusing convalescent plasma stand as a potent cell therapy for COVID-19 patients. This investigational treatment uses plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2, the virus that causes COVID-19. Plasma therapy entails the use of plasma or specific, fractioned, antibodies, along with other immunoglobulins (IGs) and possibly other therapeutic molecules harvested from immunized individuals or convalescent persons 19 . Plasma therapy has a long history of safety, and even efficacy, since the Spanish flu in 1917-1918 19, 20 . While the mechanism of action of plasma therapy remains not fully understood, the functional benefits have been largely ascribed to the purified neutralizing antibodies of the convalescent plasma 19, 20 . A meta-analysis of English-language journals from 1918 to 1925 reveals that the overall mortality rate was 16% among treated patients compared to 37% among controls, indicating difference in fatality between the treatment and control groups at 8% to 26% 20 . Note that the meta-analysis study 20 was based on only eight studies with many methodologic limitations, including lack of blinding, randomization, or placebo-controlled arm. Subsequent to the Spanish flu pandemic, the treatment with convalescent plasma has been studied in similar outbreaks of respiratory infections, such as the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic 19, 20 . Whereas small clinical trials and anecdotal accounts of convalescent plasma suggest safety and efficacy of plasma treatment in these previous outbreaks 21 , its potency in COVID-19 requires carefully designed and rigorous assessment of these clinical trials as discussed subsequently.

The still limited evidence but massively accumulating interest in the safety and efficacy of convalescent plasma treatments may provide the basis for compassionate use of these therapies for COVID-19 in the United States. Indeed, a review of the literature from 2020 alone shows that there are already 152 publications, although most are review and commentary articles, and protocol descriptions, on the theme of convalescent plasma treatments for COVID-19. Notable clinical research reports include: (1) The small study on six Chinese patients diagnosed with COVID-19, who subsequently received ABO-compatible convalescent plasma, demonstrating immediate increase of antibody titers in two patients and elimination of the virus in two other patients 22 .

(2) Another small study on ten severe COVID-19 Chinese patients revealed that nine patients displayed increased neutralizing antibody titers, and the viral load in seven patients becoming undetectable by day seven post-infusion of convalescent plasma, but only 3 exhibited improved respiratory function 23 . (3) Another study on five critically ill COVID-19 patients revealed viral loads decreased and became negative by day 12, and three patients were discharged by about 50 days, while 2 patients remained in stable condition at 37 days after convalescent plasma infusion 24 . (4) In six end-stage COVID-19 patients, convalescent plasma effectively induced viral shedding with the SARS-CoV-2 RNA undetectable by day 3 post-infusion of convalescent plasma, but five patients eventually died 25 ; (5) In South Korea, two severe COVID-19 patients treated with convalescent plasma with both showing favorable outcomes including being weaned from mechanical ventilators and/or extubated with SARS-CoV-2 negative after days 20-26 of convalescent plasma infusion 26 .

From these five small clinical case reports, the following protocol specifics may require optimization in order to further assess the safety and efficacy of convalescent plasma treatment for COVID-19. (1) The small number of patients is clearly a limiting factor in all these studies. (2) Once the number of patients to be enrolled is increased, there is a need for proper control and randomization of treatments, as well as blinding of the treating physicians. (3) The timing of convalescent plasma infusion and its doses and the need for booster shots will require careful considerations. For example, in Duan's study 23 , patients were infused with convalescent plasma at around 16 days of symptom onset, while in Shen's study 24 , patients received convalescent plasma at around 21 days after symptom onset. The recognition of positive outcomes may depend on the early initiation of convalescent plasma infusion and may be the need for subsequent booster treatment. Additionally, in Duan's study 23 , one dose of 200 ml of convalescent plasma with the neutralizing antibody titers above 1:640 was specified. In Shen's study 24 , it was 400 ml of convalescent plasma with the neutralizing antibody titer set at 1:1000. Finding the optimal timing and dose will improve the safety and efficacy of convalescent plasma. (4) Related to the timing of convalescent plasma infusion, the severity of the disease is likely to impact on the treatment outcomes. In all these five clinical studies, it is understandable that because convalescent plasma treatment remains experimental, the target population is initially the severe or critically ill patients, who have high mortality and worst morbidity, which may mask the potential functional benefits of the treatment. Future treatments may need to enroll those mild COVID-19 patients or those who are in the early stages of the disease. (5) The treatment profile of the patients will need to be carefully charted, noting the drugs and ventilator supportive care among others, in order to delineate the true effects of convalescent plasma infusion or the possibility of additive effects of convalescent plasma with antiviral agents and immunomodulatory drugs. (6) The patient's preexisting health condition is equally an important factor in treatment outcomes and disease progression. In addition to COVID-19, immune-related diseases may worsen the presenting pathology, which will likely require not only eliminating SARS-CoV-2 but also addressing the multifactorial manifestations of disease. (7) The age, gender, ethnicity, genetic factors, and other pertinent patient profiles will need to be factored into the final analysis of the treatment outcomes as this will further guide optimization of the convalescent plasma treatment. Clearly, there remain several factors in order to advance the widespread use of convalescent plasma for treating COVID-19. However, at the minimum, the transparency in reporting the detailed methods and treatment outcomes will ensure rigorous assessment of the true functional effects of convalescent plasma. A glance at the clinicaltrials.gov website reveals 173 ongoing clinical trials on the use of convalescent plasma for COVID-19. Recognition of the factors mentioned earlier will allow direct comparisons of protocols and safety and efficacy readouts across these clinical trials and further evaluate the potential of convalescent plasma for COVID-19.

As noted earlier, plasma therapy involves the use of convalescent plasma, but also the plasma-active components specifically IGs. Under the guise of passive immunity against pathogens in viral epidemics, convalescent plasma is considered the first-line passive immunotherapy since the 1918 Spanish flu and the modern viral epidemics (2003 SARS-CoV-1, 2009-2010 H1N1, and 2012 MERS-CoV), and now Covid-19 27, 28 . The last several decades have witnessed advancements in molecular technology toward the purification and manufacture of plasma-derived IG as a drug therapy 27, 28 . Toward this end, human IG formulations have been advanced as the second line of passive immunotherapies against these diseases 27, 28 . The rationale of human IG for intravenous use (IVIG) is thus based on the similar etiology and inflammatory pathogenesis of SARS-CoV-2 infection to diseases for which the use of IVIG has already been approved by the FDA 29 . According to clinicaltrials.gov, there are 40 trials using IG for COVID-19. Similar to convalescent plasma treatment, the mechanism of action ascribed to IG therapy is to boost the immune response of the body against SARS-CoV-2.

Along this line of boosting the immune system of COVID-19 patients, mesenchymal stem cells (MSCs) possess secretory functions of robust immunomodulatory biologics [30] [31] [32] [33] [34] . Because COVID-19 manifests a massive inflammatory pathology in the lung, characterized by pulmonary edema and an over-reactive immune response, which can lead to hypoxia, respiratory distress, and lung damage, finding a treatment designed to sequester this aberrant inflammation and immune response may prove beneficial against COVID-19 33 . Accordingly, cognizant that abrogating COVID-19 may depend on the patients' properly functioning immune system, the transplantation of MSCs has been proposed to propel the host immune system to effectively eliminate the virus. MSCs display potent antiinflammatory and immunomodulatory properties. Indeed, our group and many others have shown that MSCs exert anti-inflammatory effects and even repair lung damage 34 . Although MSCs have been the major cell type for cell therapy in COVID-19, non-MSC stem cells, such as umbilical cord blood monocytes 35, 36 , that similarly target the inflammatory and immune pathways and promote other regenerative mechanisms (e.g., tissue repair), are also being tested. Interestingly, intravenous administration of MSCs has the natural preponderance to migrate preferentially to the lungs allowing for the first-pass treatment of pulmonary diseases 33, 34 , such as COVID-19. Moreover, the long track record of safety profile of MSCs for hematologic diseases may expedite their clinical entry for novel indications; indeed, clinicaltrials.gov reveals 31 ongoing studies using stem cell therapy for COVID-19. Preliminary reports in China and the United States suggest solid safety outcomes in patients who have received MSCs and their exosomes 31, 32 . Together with convalescent plasma and IG treatments, stem cell therapies may offer an innovative approach in fostering immunomodulatory regulation of COVID-19. Moreover, although the lung stands as the main pathological organ in COVID-19, recent studies have implicated extra-lung organs, including the heart and the brain, as well as the gut, suggesting that targeting these organs may prove beneficial in treating the disease. Indeed, combining the envisioned vaccines and immunomodulatory treatments with novel strategies, such as altering the gut microbiome 37-41 , will likely enhance the overall prognosis of COVID-19.

Science and medicine may take time to advance a vaccine, antiviral drug, convalescent plasma treatment, and IG and stem cell therapies to the clinic. Mortality rate ranges from 0.1% to as high as 10%, with the elderly (>65 years of age) and those with preexisting immune-related and inflammatory diseases (hypertension, diabetes, heart diseases), showing higher incidence of mortality [42] [43] [44] . Given the morbidity not only in the acute stage, but the realization of equally devastating long-term effects, including cardiovascular and cerebrovascular consequences [45] [46] [47] [48] [49] , warrants immediate action to at least lessen the spread of the virus. Without access to the vaccine and other proven therapies, just like in 1918 Spanish flu era, the best course of action for the meantime is practicing social distancing and good hygiene, which represents a logical strategy to curve the course and to address the disillusioned comfort of COVID-19.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Mia C. Borlongan https://orcid.org/0000-0003-3223-8374

Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. Version 2

Gender-related differences in the characteristics of problem gamblers using a gambling helpline

Traffic accident statistics and risk perceptions in Japan and the United States

Maps & trends-Tracking global cases and tracking critical data

Covid-19 -navigating the uncharted

Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review

Applying principles of behaviour change to reduce SARS-CoV-2 transmission

Respiratory virus shedding in exhaled breath and efficacy of face masks

The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region

SARS -CoV-2: reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis). Med Hypotheses

Coronavirus disease 2019 in geriatrics and long-term care: the abcds of COVID-19

Pandemics: avoiding the mistakes of 1918

A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Children and encephalitis lethargica: a historical review

Influenza virus and neurological diseases

The relationship between encephalitis lethargica and influenza: a critical analysis

Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

Metaanalysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Convalescent plasma study group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory metaanalysis Version 2

Treatment with convalescent plasma for COVID-19 patients in Wuhan

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Effect of convalescent plasma therapy on viral shedding and survival in covid-19 patients

Use of Convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea

Active therapy with passive immunotherapy may be effective in the fight against Covid-19

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

SARS-CoV-2 inflammatory syndrome. Clinical features and rationale for immunological treatment

Expanded umbilical cord mesenchymal stem cells (uc-mscs) as a therapeutic strategy in managing critically ill covid-19 patients: the case for compassionate use

Transplantation of ACE2 À mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia

Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. Version 2

Advancing stem cell therapy for repair of damaged lung microvasculature in amyotrophic lateral sclerosis

Human umbilical cord blood-derived monocytes improve cognitive deficits and reduce amyloid-b pathology in PSAPP mice

Monocytes are essential for the neuroprotective effect of human cord blood cells following middle cerebral artery occlusion in rat

A gut feeling about stroke reveals gut-brain axis' active role in homeostasis and dysbiosis

Gut microbiome: lactation, childbirth, lung dysbiosis, animal modeling, stem cell treatment, and CNS disorders

A gutsy move for cell-based regenerative medicine in Parkinson's disease: targeting the gut microbiome to sequester inflammation and neurotoxicity

Gutting the brain of inflammation: a key role of gut microbiome in human umbilical cord blood plasma therapy in Parkinson's disease model

Probiotics and prebiotics as a therapeutic strategy to improve memory in a model of middle-aged rats

Characteristics and outcomes of coronavirus disease patients under nonsurge conditions

Time-to-death approach in revealing chronicity and severity of covid-19 across the world

A geroscience perspective on COVID-19 mortality

Neurologic complications of COVID-19

COVID-19 and the cerebro-cardiovascular systems: what do we know so far?

Potential effects of coronaviruses on the cardiovascular system: a review

Excess neurological death in New York City after the emergence of COVID-19

A systematic review of neurological symptoms and complications of COVID-19